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Background: The development of a reactive tumour stroma is a hallmark of tumour progression and pro-
nounced tumour stroma is generally considered to be associated with clinical aggressiveness. The variability
between tumour types regarding stroma fraction, and its prognosis associations, have not been systemati-
cally analysed.
Methods: Using an objective machine-learning method we quantified the tumour stroma in 16 solid cancer
types from 2732 patients, representing retrospective tissue collections of surgically resected primary
tumours. Image analysis performed tissue segmentation into stromal and epithelial compartment based on
pan-cytokeratin staining and autofluorescence patterns.
Findings: The stroma fraction was highly variable within and across the tumour types, with kidney cancer
showing the lowest and pancreato-biliary type periampullary cancer showing the highest stroma proportion
(median 19% and 73% respectively). Adjusted Cox regression models revealed both positive (pancreato-bili-
ary type periampullary cancer and oestrogen negative breast cancer, HR(95%CI)=0.56(0.34-0.92) and HR
(95%CI)=0.41(0.17-0.98) respectively) and negative (intestinal type periampullary cancer, HR(95%CI)=3.59
(1.49-8.62)) associations of the tumour stroma fraction with survival.heyeuski).
B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
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Added value of this study
Here we developed and applied a standa
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2 P. Micke et al. / EBioMedicine 65 (2021) 103269Interpretation: Our study provides an objective quantification of the tumour stroma fraction across major
types of solid cancer. Findings strongly argue against the commonly promoted view of a general associations
between high stroma abundance and poor prognosis. The results also suggest that full exploitation of the
prognostic potential of tumour stroma requires analyses that go beyond determination of stroma abundance.
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ur type.1. Introduction
The malignant transformation of cancer cells is accompanied or
even preceded by changes in the surrounding stroma [1]. The tumour
stroma is histologically an integral part of cancer tissue and repre-
sents a complex composition of different cell types, including fibro-
blasts, immune cells and cells of the vasculature, and extracellular
matrix [2]. There is strong evidence that tumorigenesis is controlled
by the complex interaction between cancer cells and stroma ele-
ments and numerous experimental studies suggest that the tumour
stroma exerts tumour-promoting effects [38]. In line with this,
many stroma features were identified that were related to tumour
aggressiveness and ultimately impact patient outcome [3, 9-11].Consequently, the concept evolved that the development of the
tumour stroma supports tumorigenesis and that these changes can
be harnessed as prognostic or predictive biomarkers. Indeed, simply
the amount of stroma in relation to the amount of tumour, can pro-
vide prognostic information. A higher amount of stroma, measured
as stroma fraction assessed visually on diagnostic haematoxylin-
eosin sections, was associated with shorter survival in many solid
tumours (reviewed in [12]). However, the previous studies evaluated
only one tumour type by the time and methodological aspects as
well as publication bias complicate the comparison between different
findings and makes a comprehensive interpretation difficult. The
development of new image analysis systems [13, 14] provides the
opportunity to evaluate the tumour stroma in a hitherto unrevealed
resolution and accuracy. The aim of the study was to apply these
advanced techniques to evaluate the tumour stroma fraction in the
most common human solid tumour types.2. Methods
2.1. Material
Cancer cohorts were procured from different Scandinavian cancer
centres (Table 1) and were provided as tissue micro arrays (TMA).
The TMAs were constructed from resection specimens of operated
cancer patients. Usually, each cancer tissue was represented by 1 to 2
tissue cores with core diameter between 1 and 1,5 mm. The individ-
ual cohorts used for the study were principally based on the location
of the cancer, e.g. lung, breast or periampullary cancer, and have
been published previously as described below. We further separated
histologically, biologically and clinically different subgroups for our
analysis, resulting in 16 different cancer groups. Detailed cohort
description is available in Supplementary Materials.
For the current study, only cases with invasive carcinomas and
with available survival data were included in the analysis. Specific
exclusion criteria may have been applied according to the guidance
from the cohorts’ providers and are described in the Supplementary
Materials.2.2. Immuno-staining and image analysis
For the immunofluorescence staining, 4 mm thick sections were
de-paraffinized, rehydrated and rinsed in distilled H2O. The staining
procedure was described in details before [13, 15]. In short, a cocktail
of antibodies was used to detect epithelial (cancer) tissue: anti-
Ecadherin (Mouse/Clone 36, BD Biosciences/610182, 1:5000),
antipan Cytokeratin (Mouse/[C11], Abcam, San Francisco/ab7753,
1:1000) and antipan Cytokeratin (Mouse/AE1/AE3, Thermo Fisher
Scientific/MA513156, 1:500). The staining was visualized by the flu-
orophore Opal 690 (FP1497001KT, Akoya Biosciences, MA, USA).
Stained tissue was scanned with the Vectra Polaris system (Akoya
Biosciences) at resolution of 0.5 mm per 1 pixel. The multiplex stain-
ing included also staining with other markers for different subsets of
immune cells (Mezheyeuski in preparation) but were not used in this
study.
Table 1
Tumour types used in the study.
TUMOUR code Tumour type n Ref.
1 RCC Renal Cell Cancer 219 [35, 36]
2 CC Colon Cancer 351 [37]
3 OVC Ovarian Carcinoma 148 [38, 39]
4 ENC Endometrial Cancer 301 [40, 41]
5 UBC Urine Bladder Cancer 210 [42]
6 LUSC Lung Squamous Cell Cancer 90 [43]
7 RC Rectal Cancer 146 [37]
8 HGSC High Grade Serous Ovarian Cancer 49 [44]
9 PACi Periampullary Cancer, Intestinal type 61 [45, 46]
10 LUAD Lung Adenocarcinoma 171 [43]
11 SC Stomach Cancer 49 [47, 48]
12 GECA Gastroesophageal Junction
Adenocarcinoma
80 [47, 48]
13 BRC ER- Breast Cancer, ER-negative 50
14 PC Prostate Cancer 241 [49]
15 BRC ER+ Breast Cancer, ER-positive 471
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the inForm Analysis software (Akoya Biosciences), where tissue was
classified into three types: Epithelial (Tumor), Stroma and blank
areas. Machine learning function based on the built-in inForm soft-
ware (Akoya Biosciences) was applied for tissue segmentation using
expression data of cytokeratin/E-cadherin, DAPI staining and spec-
trally unmixed autofluorescence. Each of 7918 images was reviewed
by pathologists (PM, IH, SM, SK, AM) and by HistoOne AB (Uppsala,
Sweden): samples which did not contain invasive tumour or were
damaged, were excluded completely while other samples were
curated manually for the exclusion of necrosis or artefacts. Addition-
ally, each sample was quality controlled with regard to the presence
of malignant tissue (with associated stroma) of invasive cancer and
regions of cancer in situ or regions with non-malignant tissue and
associated stroma were manually excluded.
The images were coded according to the position of the TMA core
on the slide. The ‘key’ to match TMAs to patient IDs was received
from cohort providers after the curation was completed. Thus, all
involved pathologists were blinded concerning any clinical data,
except the affiliation of the sample to certain cohort. The TMA/image
to patient matching procedure was performed at the final stages of
the data processing.
2.3. Data processing
Data processing was performed using R software (version 3.5.1).
The stroma fraction was computed: stroma fraction = stroma area /
(stroma area + epithelial area). In cases where more than one TMA
core represented a single tumour, the calculation of the stroma frac-
tion was processed by assuming the existing material as one sample
(i.e. to avoid unequal impact from cores of different size).
2.4. Statistics
Statistical analyses were performed using R (version 3.5.1) and
SPSS V20 (SPSS Inc., Chicago, IL). Overall survival, defined as time
from surgery for primary tumour to date of death from any cause,
was the defined analytical endpoint. Patients were censored in case
of discontinued follow-up. Kaplan Meier survival estimates were
computed and visualized using the “survival” and “survminer” pack-
ages for R. Log-Rank test was used for comparisons between patient
groups. For the survival analyses for each tumour type, patients were
grouped based on median stroma fraction as cut-off. Additionally, to
control for potential bias with improper cut-off selection, stromafraction values were used as continuous values, rounded to first deci-
mal and tested in Cox regression models. To estimate relative hazards
in both univariable and multivariable models, a Cox proportional
hazards model was used with dichotomized stroma fraction (R “sur-
vival” package). P values < 0.05 were considered as statistically sig-
nificant.
The proportional hazards assumption was assessed graphically
and tested with Schoenfeldt’s test using cox.zph function (R “survival”
package). The proportional hazards assumption was violated in intes-
tinal type periampullary cancer for stroma fraction in univariable
model and for covariables stroma fraction and pT stage in the multi-
variable model. The scaled Schoenfeld residuals against the trans-
formed time were visualised by function ggcoxzph() (R “survminer”
package) and a knee point at time-scale 70 was observed. We there-
fore created modified models with (co)variables stroma fraction and
pT stage split by time segments (0 to 70, and 70 to max).
Clinicopathological parameters inclusion in multivariable models.
Patient age at diagnosis was included in all multivariable models as
co-variable, and was dichotomized with the median as cut-off. The
exception was made for breast cancer (ER+ and ER-) due to known
non-linear impact of the patient age on survival: the age groups for
the multivariable analysis in breast cancer were set up as <=50years,
>50-<65 and >=65 years. WHO performance status, pT stage, differ-
entiation grade were used as categorical variables. pN and pM stage
were dichotomized into N0 vs N>=1 or M0 vs M>=1 respectively.
Resection margin status with regard to the presence of residual
tumour was accessed as categorical variable of three categories: R0
(no residual tumour), R1 (microscopic residual tumour) or R2 (macro-
scopic residual tumour). Adjuvant and pre-surgical therapy were
assessed as present or absent, without separation for specific treat-
ment type. As a general rule, missing values of each variable were
treated as separate category. Exceptions were done for some cases
(colon cancer, prostate cancer and breast cancer) which had missing
variables for more than one clinicopathological parameter - these
cases were excluded frommultivariable models.
2.5. Role of the funding source
The funders did not have any role in the design of the study, data
collection, data analysis or data interpretation, or writing of the man-
uscript. The corresponding author had full access to all the data in
the study and had final responsibility for the decision to submit for
publication.
3. Results
The aim of our study was to provide a comprehensive and objec-
tive analysis of the tumour stroma amount in 16 different solid can-
cer types, including in total 2732 cancer patients (Table 1, Suppl.
Material, Suppl. Table 1). Using an immunofluorescent staining for
epithelial markers and a machine learning based image analysis we
calculated the stroma fraction for each individual cancer cases (Suppl.
Fig. 1).
When comparing different tumour types, we observed major dif-
ferences in the median levels of stroma fraction, ranging from less
than 25% in renal cell carcinoma to over 70% in pancreatobiliary type
periampullary cancer (Fig. 1a). Likewise, within individual tumour
types the stroma fraction varied considerably, displaying both
stroma-poor and stroma-rich cases.
To analyse the impact of the amount of stroma on overall survival,
the stroma fraction value was dichotomized into stroma high and
low groups, using the median as cut-off in each tumour type. Kaplan-
Meier analysis revealed that a higher stroma fraction was associated
with shorter survival in urinary bladder cancer and in intestinal type
periampullary cancer (Fig. 1b, Suppl. Table 2). On the other hand, in
lung squamous cell cancer a higher stroma fraction was associated
Fig. 1. Stroma fraction in solid cancer types. (a) The empirical cumulative distribution plots of the stroma fractions in 16 cancer entities. Each dot represents an individual sample,
red horizontal lines indicate the median value of stroma fraction in the respective cancer type. (b) KaplanMeier plots illustrate the overall survival in each cohort. Stroma fraction
(SF) dichotomized into stroma rich (red) and stroma poor (blue) groups (cut-off = median stroma fraction). The p-values refer to the log-rank test. (c) Forest plots of multivariable
Cox regression models representing hazard ratios of the association between stroma fraction and overall survival. For each tumour type, a square indicates the hazard ratio and the
line on either side of the square demonstrates 95% confidence interval. A higher hazard ratio indicates that a higher stroma fraction is associated with a shorter survival. Co-variables
were selected individually for each tumour type, depending on their availability and known clinical importance (Detailed information is shown in Suppl. Fig). The tumour cohorts
are described in detail in the Supplementary Material. **The proportional hazards assumption was violated in PACi and therefore the illustrated hazard ratio should be interpreted
as the mean value over time; corrected model, split into time segments before and after 70 weeks, demonstrated by grey colour.
4 P. Micke et al. / EBioMedicine 65 (2021) 103269with improved survival. These associations were also observed in a
univariable Cox regression models using continuous stroma fraction
values. After statistical correction for intestinal type periampullary
cancer the association was only demonstrated after the time segment
of 70 weeks (Suppl. Table 3 and Material and Methods).
Subsequently, we performed survival analyses adjusted for estab-
lished prognostic factors, which were selected for each tumour type
depending on relevance and data availability (Suppl. Fig. 2). In this
multivariable Cox regression model, the adverse prognostic impact of
higher stroma fraction remained significant only in intestinal type
periampullary cancer, HR(95%CI)=3.59(1.49-8.62), when illustrated
as the mean value over time (Fig. 1c). Interesting, similar to univari-
able analysis, when the model was split to time segments, stroma
fraction demonstrated prognostic impact only after 70 weeks of
patients survival after surgery (HR(95%CI)=5.78(1.87-18.40),
p=0.0024), but not during first 70 weeks (HR(95%CI)=1.57(0.43-5.75),
p=0.0024) (Fig. 1c, demonstrated by grey colour). Contrarily, in peri-
ampullary cancer pancreatobiliary type, a higher stroma fraction was
associated with improved survival, HR(95%CI)=0.56(0.34-0.92). The
same positive association was observed for oestrogen negative breast
cancer, HR(95%CI)=0.41(0.17-0.98) (Fig. 1c).4. Discussion
The study provides a comprehensive, objective assessment of
the tumour fraction in the main solid cancer types. Our data
demonstrate that the fraction of tumour stroma is highly vari-
able between and within solid cancer types. In most cancer
types (13 of 16) no significant associations of the tumour
stroma fraction and survival were observed in the multivariable
analysis. Only in one cancer type the stroma fraction indicated
prognostic unfavourable impact (periampullary cancer intestinal
type) and in two cancer types favourable impact (periampullary
cancer pancreatobiliary type and oestrogen receptor negative
breast cancer).
The majority of previous studies have indicated a negative prog-
nostic impact of a dense tumour stroma, most often measured as the
tumour stroma ratio (TSR), e.g. in colorectal cancer [1618], gastric
cancer [19], breast cancer [20, 21], cervical cancer [22], and oesopha-
geal squamous cell cancer [23]. This association was also confirmed
in a meta-analysis including 14 studies of different cancer types [12].
The studies are mainly based on careful visual annotations of whole
tumour sections and included a selection of the most desmoplastic
P. Micke et al. / EBioMedicine 65 (2021) 103269 5regions in haematoxylin and eosin stained tissue: a method devel-
oped by the group of Mesker [24].
Our approach was different as the tissue samples were not prese-
lected to present stroma rich areas, but rather consisted of regular
representative tumour regions. Moreover, our stroma evaluation was
based on highly specific immunofluorescence staining supplemented
by an objective image analysis, and was standardized for all analysed
cohorts. This allowed a reliable comparison between the different
tumour types.
With this approach, the previously described unfavourable prog-
nostic impact of the tumour stroma fraction was only observed in
two cancer types in the univariable and only one in the adjusted anal-
ysis. However, for three cancer types, a high stroma fraction was
found to correlate to an improved prognosis. Accordingly, isolated
previous studies in different cancer types indicated that higher
stroma content was associated with longer survival [2528]. These
and our studies clearly challenge the previous paradigm of the “bad
tumour stroma” and support more recent experimental findings that
reveal a tumour suppressive role of cancer-associated fibroblasts in
pancreatic cancer models [29-31], indicating that the stroma can also
act as a barrier against tumour progression, invasion and develop-
ment of distant metastasis. The specific evaluation of stroma signal-
ling that inhibit tumour development can provide novel strategies
that supplement current armamentarium of cancer therapy.
It should be noted that our strategy has certain limitations. TMA
samples represent only a minor fraction of the whole tumour tissue
and may therefore not be able to reflect adequately all aspects of
tumour architecture. Additionally, in this study we did not apply the
specific methodology for the description of the stroma abundance,
developed by Mesker et al. [24], i.e. we did not screen through the tis-
sue sample for the regions of most extensive fibrosis. Therefore, our
results should be interpreted with caution and clearly delineated
from the guided approach.
In conclusion, crude measurement of the tumour stroma content
might be insufficient for the purpose of prognostication, and it is
likely that other stromal qualities, including mechanical features,
extracellular matrix components or immune cell composition have
overriding importance in the tumorigenic process [6, 3234]. Never-
theless, we believe that our comprehensive analysis contributes, on
an elementary level, with novel perspectives on the tumour-stroma
interaction and serves as a strong starting point for further focused
studies aimed at elucidating the role of the tumour stroma fraction in
cancer.
5. Data sharing
The data regarding the methodology, image analysis, curation and
data processing as well as raw-data of stroma fraction is available
from the corresponding author by request. The data related to cohort
characteristics (clinical and pathological data etc.) can be requested
from cohort providers: the requests can be sent vie corresponding
author or directly to cohort providers (see reference publications in
Table 1).
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